Cargando…
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
Lenalidomide (also known as Revlimid(®), CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) bot...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503648/ https://www.ncbi.nlm.nih.gov/pubmed/18728702 |
_version_ | 1782158331077459968 |
---|---|
author | Hideshima, Teru Raje, Noopur Richardson, Paul G Anderson, Kenneth C |
author_facet | Hideshima, Teru Raje, Noopur Richardson, Paul G Anderson, Kenneth C |
author_sort | Hideshima, Teru |
collection | PubMed |
description | Lenalidomide (also known as Revlimid(®), CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) both preclinical models and in clinical trials. Lenalidomide: directly triggers growth arrest and/or apoptosis of drug resistant MM cells; inhibits binding of MM cells to bone marrow (BM) extracellular matrix proteins and stromal cells; modulates cytokine secretion and inhibits angiogenesis in the BM milieu; and augments host anti-tumor immunity. Lenalidomide achieved responses in patients with relapsed refractory MM. Moreover, lenalidomide with dexamethasone (Dex) demonstrates more potent anti-MM activities than Dex both in vitro and in randomized phase III clinical trials. Specifically, the combination improved overall and extent of response, as well as prolonged time to progression and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM relapsing after prior therapy. |
format | Text |
id | pubmed-2503648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-25036482008-08-26 A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma Hideshima, Teru Raje, Noopur Richardson, Paul G Anderson, Kenneth C Ther Clin Risk Manag Review Lenalidomide (also known as Revlimid(®), CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) both preclinical models and in clinical trials. Lenalidomide: directly triggers growth arrest and/or apoptosis of drug resistant MM cells; inhibits binding of MM cells to bone marrow (BM) extracellular matrix proteins and stromal cells; modulates cytokine secretion and inhibits angiogenesis in the BM milieu; and augments host anti-tumor immunity. Lenalidomide achieved responses in patients with relapsed refractory MM. Moreover, lenalidomide with dexamethasone (Dex) demonstrates more potent anti-MM activities than Dex both in vitro and in randomized phase III clinical trials. Specifically, the combination improved overall and extent of response, as well as prolonged time to progression and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM relapsing after prior therapy. Dove Medical Press 2008-02 2008-02 /pmc/articles/PMC2503648/ /pubmed/18728702 Text en © 2008 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Hideshima, Teru Raje, Noopur Richardson, Paul G Anderson, Kenneth C A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
title | A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
title_full | A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
title_fullStr | A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
title_full_unstemmed | A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
title_short | A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
title_sort | review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503648/ https://www.ncbi.nlm.nih.gov/pubmed/18728702 |
work_keys_str_mv | AT hideshimateru areviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma AT rajenoopur areviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma AT richardsonpaulg areviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma AT andersonkennethc areviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma AT hideshimateru reviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma AT rajenoopur reviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma AT richardsonpaulg reviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma AT andersonkennethc reviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma |